Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Capital Expenditures (2016 - 2025)

Amicus Therapeutics filings provide 16 years of Capital Expenditures readings, the most recent being -$2.9 million for Q4 2025.

  • On a quarterly basis, Capital Expenditures fell 1115.28% to -$2.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $73000.0, a 97.95% decrease, with the full-year FY2025 number at $73000.0, down 97.95% from a year prior.
  • Capital Expenditures hit -$2.9 million in Q4 2025 for Amicus Therapeutics, down from $2.8 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $5.4 million in Q3 2023 to a low of -$2.9 million in Q4 2025.
  • Median Capital Expenditures over the past 5 years was $612000.0 (2021), compared with a mean of $935800.0.
  • Biggest five-year swings in Capital Expenditures: soared 4050.36% in 2023 and later crashed 1115.28% in 2025.
  • Amicus Therapeutics' Capital Expenditures stood at $3.6 million in 2021, then dropped by 24.74% to $2.7 million in 2022, then crashed by 35.34% to $1.7 million in 2023, then crashed by 83.36% to $288000.0 in 2024, then crashed by 1115.28% to -$2.9 million in 2025.
  • The last three reported values for Capital Expenditures were -$2.9 million (Q4 2025), $2.8 million (Q3 2025), and -$38000.0 (Q2 2025) per Business Quant data.